U.K. national audit of extracorporeal photopheresis in cutaneous T-cell lymphoma

Real-world use of extracorporeal photopheresis for patients with cutaneous T-cell lymphoma in the United States: 2010–2015

“…In addition, ECP monotherapy was about twice as prevalent as combination therapy with an average treatment frequency of 2.6 times per month and treatment duration of 13.6 months, indicating that ECP is well tolerated among CTCL patients. In comparison, a recent national audit of ECP in CTCL in the UK reported shorter treatment duration of 9 months compared to the current study (22). The average treatment frequency and duration are aligned with the recommended regimens in CTCL treatment guidelines: 1 cycle (2 daily ECP procedures) every 2 to 4 weeks with a median time of 5 to 6 months for maximal response (18).…”

“…ECP can be reduced to 1 cycle every 6 to 12 weeks and end of ECP treatment if no relapse or back to every 2 to 4 weeks if relapses occur (18). In terms of combined therapies, the UK national audit reported that 72% patients received ECP along with a concurrent systemic treatment (22), whereas most patients (65%) received ECP as a monotherapy in the current study. In addition, our results show that interferon was the most frequently used treatment in combination with ECP, which is consistent with the finding in the UK (22).…”

British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018

“…A recent U.K. audit report of 97 patients with CTCL treated since 2010 found that 45% had received ECP as the first‐line systemic agent . The response rate at 6 months was 61% and the median length of treatment was 9 months.…”

Prolonged survival with the early use of a novel extracorporeal photopheresis regimen in patients with Sézary syndrome

“…in one of the largest cohorts of its kind to date, exceeding the OS of 39 to 65 months reported in previous studies. [14][15][16][17][18][19][20] These results may reflect the early commencement of ECP in our cohort, although there were too few patients treated at later lines to permit a formal comparison. At the same time, it is also possible that prolonged OS reflects the focus on immune modulation for the management of SS rather than the use of systemic chemotherapy, which is generally ineffective.…”